Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation

Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation

We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevir...

Full description

Saved in:
Bibliographic Details
Main Authors: Prasitsuebsai W., Cressey T., Capparelli E., Vanprapar N., Lapphra K., Chokephaibulkit K.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858800794&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/42866
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-42866
record_format dspace
spelling th-cmuir.6653943832-428662017-09-28T06:41:14Z Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation Prasitsuebsai W. Cressey T. Capparelli E. Vanprapar N. Lapphra K. Chokephaibulkit K. We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure. © 2012 by Lippincott Williams & Wilkins. 2017-09-28T06:41:14Z 2017-09-28T06:41:14Z 2012-04-01 Journal 08913668 2-s2.0-84858800794 10.1097/INF.0b013e3182401c41 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858800794&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/42866
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure. © 2012 by Lippincott Williams & Wilkins.
format Journal
author Prasitsuebsai W.
Cressey T.
Capparelli E.
Vanprapar N.
Lapphra K.
Chokephaibulkit K.
spellingShingle Prasitsuebsai W.
Cressey T.
Capparelli E.
Vanprapar N.
Lapphra K.
Chokephaibulkit K.
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
author_facet Prasitsuebsai W.
Cressey T.
Capparelli E.
Vanprapar N.
Lapphra K.
Chokephaibulkit K.
author_sort Prasitsuebsai W.
title Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
title_short Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
title_full Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
title_fullStr Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
title_full_unstemmed Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
title_sort pharmacokinetics of nevirapine in hiv and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858800794&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/42866
_version_ 1681422270614994944

Similar Items